Mental disorders in drug users have received increasing attention. However, there are no any epidemiologic data available in regard to substance use disorders (SUD) and other mental disorders in drug users in Yunnan, one region that is hit hardest by epidemic of drug use in China.

To investigate the co-prevalence of SUD and a common mental disorder, axisⅠdisorders, among Yunnan's drug users.

A cross-sectional survey was conducted among a convenient sample of 598 male drug users who received detoxification treatment from the 5th Compulsory Detention and Forced Detoxification Center of Yunnan Province and Dali Compulsory Detention and Forced Detoxification Center between August and November, 2020. According to the diagnosis of SUD, the participants were divided into three groups: opioid use disorder group (n=245) , methamphetamine use disorder group (n=197) and double use disorder group (n=146) . The Chinese version of SCID-Ⅰ/P was used to assess the prevalence of common axisⅠmental disorders (psychosis disorder, affective disorder, alcohol use disorder, and sedative-hypnotic use disorder) . The lifetime prevalence of these disorders among the three groups was compared.

Among the 598 cases, there were 588 cases diagnosed with SUD (opioid, methamphetamine, or both) . The lifetime prevalence of psychosis disorder, alcohol use disorder, sedative and hypnotic use disorder among the three groups was significantly different (P < 0.05) . The overall lifetime prevalence of schizophrenia, other primary and drug induced psychotic disorders was 15.82%. The lifetime prevalence of psychotic disorder in opioid use disorder group (5.31%) was lower than that of methamphetamine use disorder group (20.30%) or that of double use disorder group (27.40%) (P<0.05) . The overall lifetime prevalence of affective disorders was 21.77%. To be specific, the lifetime prevalence of affective disorders was 17.14% in opioid use disorder group, 25.38% in methamphetamine use disorder group, and 24.66% in double use disorder group. The overall lifetime prevalence of alcohol use disorder was 42.18%. Specifically, opioid use disorder group had lower lifetime prevalence of alcohol use disorder than methamphetamine use disorder group (35.10% vs 45.69%) and than double use disorder group (35.10% vs 49.32%) (P<0.05) . The overall lifetime prevalence of sedative or hypnotic use disorder was 13.61%. The lifetime prevalence of sedative or hypnotic use disorder was 19.18%, 22.60% and 0 in opioid use disorder group, double use disorder group, and methamphetamine use disorder group, respectively.

The prevalence of the above-mentioned mental disorders in drug users in Yunnan Province was much higher than that in the general population. Moreover, these mental disorders may be even more prevalent in methamphetamine use disorder population than in opioid use disorder population.

目前，吸毒人群中精神疾病共患现象受到越来越多的关注，而云南省作为我国毒品流行重灾区，其吸毒人群中物质使用障碍（SUD）与其他精神疾病共患流调数据仍是空白。

了解云南省吸毒人群SUD与常见轴Ⅰ精神疾病的共患情况。

本研究为横断面调查研究，采用方便抽样法选取2020年8—11月在云南省第五强制隔离戒毒所和大理州强制隔离戒毒所进行戒毒治疗的男性戒毒学员598例为调查对象。根据戒毒学员对阿片类和甲基苯丙胺类兴奋剂（ATS）类毒品的SUD情况，将戒毒学员分为三组：阿片类SUD组（245例）、ATS类SUD组（197例）和双重SUD组（146例）。采用DSM-Ⅳ-TR轴Ⅰ障碍临床定式检查病人版（SCID-Ⅰ/P）中文版，对常见轴Ⅰ精神疾病（精神病性障碍、情感障碍、酒精SUD、镇静催眠药SUD）进行诊断，并比较不同毒品SUD戒毒学员中常见轴Ⅰ精神疾病的终生患病率。

云南省598例男性戒毒学员中存在阿片类SUD、ATS类SUD和双重SUD的戒毒学员共588例。三组戒毒学员精神病性障碍、酒精SUD、镇静催眠药SUD终生患病率比较，差异有统计学意义（P<0.05）。三组戒毒学员中，精神分裂症及其他原发性和物质所致精神病性障碍的终生患病率为15.82%，其中阿片类SUD组戒毒学员精神病性障碍的终生患病率（5.31%）低于ATS类SUD组（20.30%）及双重SUD组（27.40%）（P<0.05）；情感障碍的终生患病率为21.77%，阿片类SUD组、ATS类SUD组及双重SUD组戒毒学员中的终生患病率分别为17.14%、25.38%和24.66%；酒精SUD的终生患病率为42.18%，阿片类SUD组戒毒学员酒精SUD的终生患病率（35.10%）低于ATS类SUD组（45.69%）及双重SUD组（49.32%）（P<0.05）；镇静催眠药SUD的终生患病率为13.61%，阿片类SUD组、双重SUD组戒毒学员中的终生患病率分别为19.18%和22.60%，ATS类SUD组戒毒学员中无检出。

常见轴Ⅰ精神疾病在云南省SUD戒毒学员中的终生患病率均高于普通人群同类疾病的终生患病率，且这些精神疾病在ATS类SUD人群中的终生患病率又高于阿片类SUD人群。